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PREFACE
Healthcare provision in the developing world is plagued by limited resources and
high disease burdens. The notion that inexpensive, partially accurate, surrogate
diagnostic markers can advance care in this already chaotic environment retards
progress.
Accurate diagnosis is a vital first step in treating disease.
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ABSTRACT
Sub-Saharan Africa is the eye of the HIV epidemic. This study was conducted
when treatment for the majority of HIV-infected patients in low resource settings
was considered unattainable and the risks of diagnosing HIV often outweighed
the benefits. Coupled with the complexities of HIV diagnosis in infancy, children
typically were only diagnosed once already ill or not at all. Key strategies to
address the paediatric epidemic focused on preventing mother to child
transmission and reducing mortality and morbidity of infected children
predominantly with co-trimoxazole prophylaxis. Both strategies required early
diagnosis of HIV infection in infancy for monitoring prevention programs and
identifying infected children respectively. The diagnostic algorithm for resource
limited settings recommended the use of inexpensive, technically simpler HIV
antibody detection assays that are unsuitable for use in HIV-exposed children
under 12-months of age. Paradoxically this algorithm provided a barrier to HIV
diagnosis in children because of high loss to follow-up rates and death in the first
year of life.
The objective of this study was to establish an accurate, affordable diagnostic
algorithm for early diagnosis of HIV infection that could be rapidly implemented in
South Africa and benefit other resource limited settings. The HIV infection status
of 300 vertically exposed infants was determined according to first world criteria
in a prospective, cohort study at Coronation Hospital, Johannesburg over 21
months. This status was used to assess the accuracy of clinical examinations
and HIV assays in diagnosing HIV at 6-weeks, 3-, 7- and 12-months of age. The
average cost of determining an infant’s HIV infection status was measured.
A single HIV DNA PCR test at 6-weeks of age proved highly accurate in
determining HIV status at a marginally increased cost to government and was
incorporated by the South African Department of Health into national policy. The
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ultrasensitive p24 antigen assay and HIV antibody detection assays on serum
and oral fluid were identified as valuable candidates where PCR testing is
unavailable. Dried blood spot samples from heelpricks are critical for policy to be
translated into practice since skills to perform venesection in 6-week old babies
are limited. The next challenge lies in operationalising these findings at a clinical
and laboratory level to the benefit of the 300 000 South African children annually
exposed to HIV at birth. The urgency of early diagnosis has been increased by
the availability of highly effective antiretroviral therapy.
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1. INTRODUCTION
By 2005 UNAIDS estimates were that 25 million people had died from HIV/AIDS
since 1981 and 40.3 million people, the highest total yet, were living with the
disease (1). The latter includes 2.3 million children under the age of 15 years,
85% of whom are located in sub-Saharan Africa. In 2005, 700 000 children were
newly infected and 570 000 died worldwide.
Figure 1. Adults and children estimated to be living with HIV in 2005 (1)
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The South African National Department of Health’s HIV Sero-prevalence survey
of pregnant women aged 15 to 49 years demonstrated a prevalence of 29.5% in
2004 (Figure 2) (2). Considering the country’s estimated birth rate of
approximately one million per annum, this means that 29.5% of all babies born in
South Africa are vertically exposed to HIV amounting to 295 000 babies per
annum.
Figure 2. Prevalence of HIV among antenatal care attendees in South Africa
1990-2004 (2)
Prevention of Mother to Child Transmission (PMTCT) is the major prevention
strategy for paediatric HIV infection and has proved extremely successful in the
developed world in virtually eradicating vertically acquired paediatric HIV
infection. The HIV transmission rate, established by diagnosing HIV-exposed
babies, is a fundamental indicator of the efficacy of a PMTCT program and
therefore crucial to ensuring successful PMTCT programs for eliminating this
route of infection in South Africa and elsewhere. Moreover, early HIV diagnosis is
essential to identify HIV-infected children to receive comprehensive care
including antiretroviral therapy.
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The diagnosis of HIV infection in infants is more complicated than in older
children and adults where diagnostic algorithms comprising a single group of
tests viz. HIV antibody detection tests such as HIV enzyme linked
immunosorbent assays (ELISA) are used. Transplacental transfer of maternal
HIV antibodies means that all babies born to HIV infected women have HIV
antibodies (3). This precludes the use of HIV antibody detection assays for
diagnosis early in life. Instead viral detection assays which are technically more
complex and expensive are required. The maternal HIV antibodies have been
documented to persist for up to 18 months of age therefore a positive HIV ELISA
result up to this age may signify HIV exposure rather than HIV infection. The
process whereby uninfected, exposed infants gradually lose maternal HIV
antibodies and revert to having a negative HIV ELISA test is termed
seroreversion. Most exposed infants will serorevert much earlier than 18 months
of age, often by 9-12 months of age. Diagnosis in children is further complicated
in breastfed children by the ongoing risk of postnatal transmission of HIV.
In 1992, following an international workshop on “Early Diagnosis of HIV Infection
in Infants”, the HIV DNA Polymerase Chain Reaction (PCR) test was
recommended for routine infant diagnosis although HIV culture remained the
‘gold standard’ assay (4). Detection of proviral DNA by PCR was first described
in 1988, rapidly validated for clinical use (5-12) and a commercial HIV DNA PCR
test kit developed and tested (13-16). HIV DNA PCR testing on dried blood spot
(DBS) samples was achieved as early as 1991 (17-22). Other, less accurate HIV
tests for infant diagnosis under investigation at the time were in vitro antibody
production tests (6, 7, 23), detection of HIV antibodies of immunoglobulin A and
M subtype since neither isotypes are transferred transplacentally to the foetus
(24-27) and p24 antigen assays (5, 10, 12, 28). Subsequently HIV RNA assays
were shown to be highly sensitive and specific for early diagnosis of HIV (29-32)
as was reverse transcriptase activity (33). More comprehensive accounts of
these and later studies are summarized elsewhere (34, 35).
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Attempts to improve early identification of HIV-infected children in low resource
settings have centered on surrogate immunological (e.g. low CD4 counts and
hyperimmunoglobulinaemia) and clinical markers of disease (36-39) as well as
modifying the use of antibody detection assays to exclude HIV infection earlier in
infancy (40-45).
Although the concept of using HIV antibody titers to facilitate an earlier diagnosis
of HIV in infancy has been widely investigated (40, 42-48), it has not been
validated in clinical practice. Seroreversion marks the time after which the simpler
antibody detection assays are as accurate in diagnosing infants as the more
complex and costly viral detection assays but the age at which seroreversion
occurs is highly variable. This has been attributed to different patient populations
and testing systems (42). At 12-months of age the sensitivity of an HIV ELISA
test approaches 100% but the reported specificity ranges from 70% to 95% as a
consequence of false positive results from declining maternal antibodies in HIV-
uninfected infants (43, 47, 49). The clinical utility of antibody detection assays,
including rapid tests, for excluding HIV infection has not been explored in infants
younger than one year of age and is vital in settings where viral detection assays
are not yet available.
Currently, widely accepted guidelines from the Centers for Disease Control
(CDC) require at least two concordant viral detection assay results on blood
sampled on two separate occasions to establish HIV infection status in infancy
(3). The HIV DNA PCR test, a qualitative test that detects proviral DNA is
recommended for routine clinical practice. The guidelines state that the HIV tests
should be performed at more than 1 month of age and again at more than 4
months of age. The rationale for delaying the second HIV PCR test is to ensure
diagnosis of all in-utero and intrapartum (during labour and delivery) HIV
transmission. It applies only when the first test is negative and stems from a
concern that a small percentage of infections, especially those occurring
intrapartum, may not be detectable by PCR until 4 months of age (3, 50-52).
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However, if the HIV PCR test is positive then the second confirmatory test need
not be delayed.
The guidelines published by the American Academy of Pediatrics for the
diagnosis of HIV infection in infancy also require at least two but preferably three
HIV PCR tests and testing for seroreversion in uninfected children at age 12 and
24 months (52). The cost effectiveness of this approach in the developed world,
estimated to be US $24 million extra to identify one additional HIV-infected child
has been questioned (51).
Guidelines for infant diagnosis in South Africa recommending at least two HIV
DNA PCR tests per patient where ‘ideal conditions’ existed were published in
2001 by the Southern African HIV Clinicians Society (53). These applied to very
few children whose families could afford access to private healthcare. In the
same year and in line with national policy, the Gauteng Department of Health’s
HIV paediatric guidelines recommended the archetypal ‘low resource setting’
infant diagnostic protocol viz. that all vertically exposed children be followed up
on co-trimoxazole prophylaxis until their HIV infection status was determined at
12 months of age by an HIV ELISA test (3, 54, 55). This strategy entailed
initiating PMTCT follow-up services for approximately 250 000 babies per annum
(2), 70% of whom were HIV-exposed but uninfected. With limited public
healthcare resources to accommodate this policy, efforts expended to identify
HIV-infected pregnant women in PMTCT programs failed to translate into
improved care for HIV-exposed babies. This became apparent in 2002 when the
first report of the 18 South African PMTCT pilot sites initiated in 2000 was unable
to provide HIV transmission rates because of high loss to follow-up rates of
infants prior to HIV testing and concluded that the “policy of postpartum care of
children was largely unrealistic” (56).
In 2004 The Star newspaper printed a retraction of a front page article claiming
that Gauteng’s PMTCT program had “saved 58 000 babies” explaining that this
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figure was unlikely to be representative since it had been extrapolated from only
3% of infants who had returned at 12 months for HIV testing (57). To date, the
national HIV transmission rate and hence the efficacy of the most important
prevention strategy for HIV infection of children is unknown and will remain so
until widespread infant diagnosis is implemented (58).
When this study was planned in 2000 the national antenatal clinic HIV prevalence
rate was 24.5% putting almost a quarter of all babies born in the country at risk of
HIV infection and in need of PMTCT follow up care; an HIV DNA PCR test cost
approximately 10 times more than an HIV ELISA test and was unavailable in the
public health care setting where the majority of HIV-exposed babies are seen. No
antiretroviral drugs were available for treatment of HIV in the public sector.
Preliminary investigations leading to this study confirmed that a single HIV DNA
PCR test at any age in conjunction with a clinical assessment was 100%
sensitive and 98.5% specific in 101 children (59). In the same cohort, HIV ELISA
readings at various ages were compared to the HIV status of the infant and a
utility for these readings in diagnosing HIV earlier than 12 months of age was
suggested (48).
Based on experience of PMTCT follow-up programs locally and in sub-Saharan
Africa it became apparent that addressing the paediatric HIV epidemic hinged on
diagnosing HIV infection as early in life as possible (55). Achieving this goal by
defining an accurate, affordable diagnostic algorithm for low resource settings
prompted this study.
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2. RESEARCH AIMS
To advance diagnosis of HIV infection in infants:
- investigate alternative diagnostic protocols by assessing several HIV tests (both
HIV antibody and viral detection assays) to establish accurate, cost-effective
options for the diversity of poorly resourced settings where paediatric HIV
infection is prevalent
- establish the cost of replacing the diagnostic protocol used in South Africa (at
the time) with an alternative protocol that would provide a diagnosis early in
infancy
- disseminate the results of this work to contribute towards practice guidelines,
standard operating procedures and training materials to advocate for earlier
diagnosis of infants in South Africa and other low resource settings
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3. METHODS
All HIV infected women delivering at Coronation Women and Children’s Hospital
(CWCH) who could be contacted telephonically were eligible to enroll their infants
at 6 weeks of age. For practical considerations, enrollment was limited to seven
patients per week. The protocol was approved by the Ethics Committee of the
University of the Witwatersrand (Protocol number M02-01-16) (Appendix 1). The
signed informed consent (Appendix 2) and patient identifying data (Appendix 3)
were filed separately from the clinical documents to maintain confidentiality. The
study protocol was optimized according to the outcomes of a pilot study
undertaken at the same facility in 2001.
The sample size was calculated using SAS software version 9 by estimating loss
to follow-up (including deaths), vertical transmission and breastfeeding rates. A
sample size of 300 was chosen in order to detect a difference of <1% in
sensitivity or specificity of a 6-week HIV DNA PCR test assuming the sensitivity
and specificity of the HIV DNA PCR test were between 90 and 99%.
Infants were managed according to national ‘standard of care’ guidelines (54)
except that an earlier diagnosis was available at 4 months of age. Thus, all
infants were followed to 12 months of age but their HIV infection status was
established earlier according to CDC guidelines, which provided the ‘gold
standard’ against which other HIV test results were assessed (Table 1). No
antiretroviral therapy other than Nevirapine for PMTCT was available to these
infants.
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Table 1. STUDY VISIT SCHEDULE
ASSESSMENT 6 WEEKS
3
MONTHS
4
MONTHS
7
MONTHS
12
MONTHS
History & clinical examination X X X X
Laboratory tests X*
HIV DNA PCR (qualitative) X (DBS) X (X) (X)
HIV RNA PCR (quantitative) X
HIV ELISA (serum) X X X !
HIV ELISA (oral fluid) X
HIV status disclosure X
(DBS) Dried blood spot for storage and subsequent analysis
* Further testing according to CDC guidelines if required (e.g. if two HIV PCR results are discrepant)
(X) Specimen to be separated, frozen and stored for later processing where necessary
! Children breastfed in the preceding 3 months to undergo further testing
Study visits were defined as follows:
6 week visit - between 5 weeks and 8 weeks of age
3 month visit - 2 weeks on either side of 3 months of age
4 month visit - at least 2 weeks after the 3 month visit
7 month visit - between 7 and 8 months of age
12 month visit - between 11 and 12 months of age
The protocol for sampling, preparation and storage of blood and oral fluid is
detailed in Appendix 4. Clinical examination findings were standardized
(Appendix 5) and clinical data sheets devised to document findings at each visit
(Appendix 6). To ensure an unbiased clinical assessment, paediatricians and
medical officers were blinded to the infants’ HIV test results. At each clinical visit
the infants’ HIV infection status was determined according to the clinical findings.
The infants’ HIV infection status was documented as ‘uninfected’, ‘infected’ or
‘unknown’.
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HIV tests detailed in Table 1 and Appendix 4 were performed prospectively on
blood:
HIV DNA PCR: Roche Amplicor HIV-1 DNA version 1.5 assay
HIV RNA PCR: Roche Amplicor Monitor version 1.5 assay
(Roche Diagnostic Systems Inc, Branchburg, NJ)
HIV ELISA: HIV-1/HIV-2 III Plus (IMx System)
(Abbott Diagnostics Division, Wiesbaden, Germany)
and oral fluid:
OraSure collection device (Orasure Technologies, Inc., Bethlehem, PA)
and the Vironostika Microelisa system
(Organon Teknika Corporation, Durham, NC)
Oraquick Rapid HIV-1/2 Antibody test
(Orasure Technologies, Inc., Bethlehem, PA).
HIV DNA PCR on stored dried blood spots and the Ultrasensitive p24 Antigen
assay (HIV-1 p24 Ag Ultra kit, PerkinElmer Life Sciences, Turku, Finland) on
stored plasma were performed later once the methodology of these assays had
been optimized.
The costing substudy datasheet (Appendix 7) was designed and tested for
completion on a convenience sample of 30 patients at each of their five visits. For
practical reasons two new patients were randomly enrolled per week.
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4. RESULTS
The outcomes are presented as six publications and unpublished work.
Reference is made to additional publications emanating from the study.
Inconsistencies are outlined in Appendix 8.
Infants were enrolled between January and October 2002 and their follow up
completed by September 2003. The infant’s 3-month HIV ELISA test served as a
check of the mother’s positive HIV status since her HIV test results were not
always available due to incomplete antenatal clinic records. To achieve the
sample size of 300, 302 infants were enrolled. One infant was excluded on the
basis of a negative 3-month HIV ELISA result and although the mother’s positive
HIV status was subsequently confirmed there was no definitive evidence of HIV
exposure at birth. A second infant was initially excluded because no 6-week HIV
PCR results were available until the dried blood spot HIV DNA PCR tests were
processed after the study was completed. Of the 300 infants, 151 were female
and 149 were male.
Figure 3 illustrates the study follow-up rates and provides an update to Figure 1A
in Publication 1 when study visits were incomplete. The intervals at which 10
(38.5%) of the 26 HIV-infected children died are shown. This concurs with a later
study demonstrating that 35% of HIV-infected infants in sub-Saharan Africa die
within the first year of life (60). No HIV-uninfected infants were known to have
died during the study period. By 12-months of age 57 (19%) patients had
defaulted from the study.
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Determination of the HIV infection status of 301 infants (Publication 2)
No discordant qualitative or quantitative HIV PCR test result was recorded for
any infant irrespective of their age.
All 26 infants diagnosed as HIV-infected fulfilled the CDC criteria (3). At least two
positive HIV PCR test results at 6-weeks and 3-months of age were recorded for
24 infants. Two infants died prior to the 3-month visit but were clinically
symptomatic and tested HIV DNA and RNA PCR positive at 6-weeks of age. A
third HIV DNA PCR test was prospectively performed in six (23%) infected
infants at 4-months of age because they appeared clinically unaffected, evidence
of the lack of sensitivity of a clinical examination early in infancy.
Of the 275 infants diagnosed as uninfected, 30 (10%) did not fulfill CDC criteria
chiefly because they were lost to follow up. Seven infants defaulted before the 3-
month visit but were considered uninfected at 6-weeks of age on the basis of
being clinically asymptomatic and having three negative HIV PCR results (viz.
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Figure 3. Study visit attendance
Visits missed 0 7 15 36 57
Deaths 0 2 3 5 10
Visits attended 301 292 283 260 234
6wks 3mo 4mo 7mo 12mo
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liquid blood HIV DNA and RNA PCR and DBS HIV DNA PCR (Table 1)). The
remaining 23 infants all had at least two negative HIV PCR results at 6-weeks
and 3-months of age.
The balance of 245 infants diagnosed as uninfected fulfilled CDC criteria in that
they all had two negative HIV PCR results at 6-weeks and 3-months of age, and
either seroreverted by 12-months of age (n=124) or had an additional negative
HIV PCR result obtained retrospectively on stored sample from their 12- or 7-
month visit (n=121).
Clinical diagnosis of HIV infection in infancy
Table 2 illustrates the outcome of the prospective clinical assessments performed
by the study doctors. Despite being performed by experienced doctors, a clinical
examination alone at 6-weeks of age identified a little over half of HIV-infected
infants although sensitivity did improve dramatically with age.
One year after commencement of this study, a clinical algorithm to identify
children with suspected HIV infection for HIV testing was incorporated into the
South African Integrated Management of Childhood Illness (IMCI) guidelines (38,
61). When the clinical findings of this study were retrospectively analysed
according to the IMCI algorithm, significantly less HIV-infected children were
identified as evidenced by lower sensitivities in all age groups under 1 year (38,
62) (Table 2). By 12 months of age the IMCI algorithm identified only half of all
HIV-infected infants but even more worrying was its failure to detect 50% of HIV-
infected study infants who died before 12-months of age (62). Clinical
examination, although useful when used in conjunction with HIV testing, fails to
identify infants at risk of HIV-related deaths.
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The accuracy of the “Study doctors’ assessments” is over-estimated since infants of “unknown status” were excluded.
The accuracy of the “IMCI clinical algorithm” was determined retrospectively.
N= negative; P= positive; SN= sensitivity; SP= specificity; PPV= positive predictive value; NPV= negative predictive value
* statistically significantly different p < 0.05 (χ2 test) ; ** statistically significantly different p < 0.005 (χ2 test)
Table 2. PERFORMANCE OF CLINICAL ASSESSMENTS
Age n True HIV
status
Clinical assessments
by study doctors
Study doctors’ assessments
(according to Appendix 5)
IMCI clinical algorithm
N P N P Unknown
[% of total]
SN
%
SP
%
PPV
%
NPV
%
SN
%
SP
%
PPV
%
NPV
%
6 weeks 301 275 26 210 33 58
[19]
56** 90** 30 96 17 97 30 94
3 months 290 267 23 224 21 45
[16]
67** 96* 57 97* 11 100 100 93
7 months 258 238 20 223 18 17
[7]
94** 99.5 89 99.5* 47 99.6 89 96
12 months 234 219 15 208 15 11
[5]
93** 99.5 87 99.5* 50 99.5 88 97
Improving the clinical utility of HIV antibody assays in infants
The pattern of HIV antibody changes over time (Figure 4) was similar to that
previously documented for vertically exposed South African infants where the
divergent pattern of HIV antibodies in infected and uninfected infants emerged
at about 6 months of age (43).
Figure 4. Serial HIV ELISA readings from 301 HIV-exposed infants.
The graph depicts the mean ± 95% confidence intervals of serial ELISA readings
for 26 HIV-infected and 275 HIV-uninfected infants at median ages of 3.0, 7.5
and 12.1 months respectively. Results are available for 15 infected and 212
uninfected infants at all three time points. At 7-months of age outliers (not
depicted here) prevent effective discrimination of HIV status on the basis of
ELISA readings but by 12-months of age there is much less overlap.
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ELISA tests deliver a qualitative result by measuring specific HIV antibodies
and using a cutoff reading, statistically set from clinical populations, above
which the test is positive and below which the test is negative. The
manufacturer’s recommended cutoff value for the ELISA reading is 1
therefore readings greater than 1 are positive (Figure 5). At 12-months of age,
122 of the 219 HIV-uninfected children (specificity = 56%) had negative HIV
ELISA results (Figure 5). If the same test results are interpreted using a
higher cutoff reading of 5, 208 of the 219 uninfected children (specificity =
95%) can be correctly identified as being HIV-uninfected.
HIV-infected children had higher ELISA readings and were clinically
symptomatic in comparison to HIV-uninfected children. Reduced antibody
production during end stage acquired immunodeficiency syndrome may result
in low HIV ELISA readings in an infected child however a clinical assessment
would readily identify such a child (47). Since virtually all 12-month old HIV-
infected children display signs and symptoms of HIV infection, the sensitivity
of the HIV ELISA test is further safeguarded (62).
All infants under 18 months of age with positive HIV ELISA results require
repeat testing to distinguish between HIV-infection and HIV-exposure. Of the
234 children tested only 26 (11%) instead of 112 (48%), using a cutoff value
of 5 and 1 respectively, would need to return for repeat testing after 12-
months of age provided they were not being breastfed. Therefore increasing
the ELISA reading cutoff from 1 to 5 at 12-months of age increased the
specificity of the HIV ELISA test by 39% whilst maintaining the sensitivity at
100%.
Further investigation is warranted to explore the earliest age at which HIV
infection can be excluded in HIV-exposed children using antibody detection
assays. In particular, rapid HIV tests on blood and oral fluid (Publication 5)
may be effective as early as 6-months of age.
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Figure 5. ELISA readings at a median of 12.1 months of age in
15 HIV-infected and 219 HIV-uninfected children
The 13-month old HIV-infected child with a reading of 8 had persistent,
multiple clinical features consistent with HIV-infection since 7-months of age.
Conversely, HIV-uninfected children with readings between 5 and 10 were
clinically asymptomatic.
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4.1 INTRODUCTION TO PUBLICATION 1
Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD.
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The study provided the first opportunity to assess the HIV transmission rate of
the CWCH PMTCT program. Additionally the efficacy of Nevirapine
administration, infant feeding practices and infant follow-up rates for the program
could be evaluated. The paper sets the scene of how routine PMTCT care is
practiced in South Africa and illustrates the importance of earlier infant diagnosis
for monitoring the efficacy of PMTCT programs and identifying HIV-infected
children for care. It suggests that the ‘low resource setting’ infant diagnostic
protocol must be revised to achieve an earlier, accurate and affordable HIV
diagnosis.
At the time of this publication, a single 6-week HIV DNA PCR test result
appeared highly accurate in determining the HIV infection status of exposed,
non-breastfed infants. This was borne out in the final analysis of 26 HIV-infected
and 274 HIV-uninfected 6-week old infants demonstrating that a single HIV DNA
PCR test performed on liquid blood yielded a sensitivity of 100%, specificity of
99.6% (99.0-100.3%) due to one false positive result, positive predictive value of
96.3% (94.2-98.4%) and negative predictive value of 100% where the bracketed
values indicate 95% confidence intervals. In Publication 2 when the cohort was
combined with two others, a single 6-week HIV DNA PCR test was shown to be
98.8% sensitive and 99.4% specific in 627 infants.
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Quantitative HIV RNA PCR results on liquid blood were available at 6-weeks of
age for 24 infected and 257 uninfected children. Results concurred with the final
HIV infection status of every child except for one false positive result of 109
copies per milliliter. Because of the very low viral copy number and previous
descriptions of low false positive results in these instances (63, 64), this was
presumed to be a false positive at the time the result was received. The
sensitivity of 100% and specificity of 99.6% of this viral load assay equals the
performance of the HIV DNA PCR assay but since it did not add any accuracy
and cost more at the time, it was not pursued further.
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4.2 INTRODUCTION TO PUBLICATION 2
Sherman GG, Cooper PA, Coovadia AH, Puren AJ, Jones SA, Mokhachane M,
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Although a single HIV DNA PCR version 1.5 assay at 6 weeks of age in the
setting of this study performed extremely well, further validation of this approach
was sought by increasing the sample size and broadening the clinical and
laboratory conditions. The study cohort was combined with two other clinical
cohorts where the HIV infection status of children had been established and 6-
week HIV DNA PCR results, performed in a different molecular laboratory, were
available for assessment.
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Infants’ access to a diagnosis is dramatically enhanced when HIV laboratory
tests can be performed on DBS. Most healthcare workers in low resource
settings would not have the skills required to venesect 6-week old babies foiling
implementation of widespread early HIV PCR testing. In contrast, blood sampling
by heelprick is widely practiced and requires less training.
This paper describes how the HIV DNA PCR test method was modified to
analyse DBS instead of liquid blood and demonstrates that the modified assay
maintains its accuracy on DBS collected from 6-week old infants. Poorly
resourced settings with high throughput routine laboratories will not have an
abundance of skilled personnel to troubleshoot therefore strategies to minimize
laboratory error are important. Examples of such strategies include using
standardized, commercially available test kits and simplifying test methods as far
as possible. The unique extraction procedure described in this paper means that
the method for performing HIV DNA PCR tests is highly similar whether on DBS
or liquid blood.
Whatman filter paper no. 1 (Whatman Inc., Maidstone, Kent, UK) (Figure 6) was
used because it is ubiquitous in laboratories and less expensive than the FDA-
approved Schleicher and Schuell filter paper (S&S 903, Whatman Inc., Sanford,
Maine, USA) (Figure 7) however, it is less absorbent resulting in blood spillage
and thereby an increased biohazard and cross contamination risk in the field.
S&S filter paper is more standardized than the Whatman filter paper with
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demarcated circles for blood collection and dedicated space for labeling the
sample. The consensus opinion amongst South African policy makers was to
adopt S&S 903 paper for DBS HIV DNA PCR testing.
Figure 6. DBS from three 6-week old infants collected on Whatman no. 1
filter paper
Figure 7. S&S 903 filter paper (Guthrie card) for DBS collection
207 NM
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The performance of the Ultrasensitive p24 Antigen ELISA using Schupbach’s
lysis buffer (65) was assessed at predominantly 6 weeks and 3 months of age on
stored plasma. This viral detection assay provides a third option for early
diagnosis of HIV in infants to add to HIV DNA and RNA PCR. At 6-weeks of age
it demonstrated equal specificity and only slightly less sensitivity at 96%
(resulting from a single false negative result). The assay is well suited to settings
where skills and equipment to perform PCR are limited. Disadvantages currently
associated with the assay, but that can be circumvented, are that the
commercially available kit is supplied with an inferior lysis buffer, pricing is
inflated and accessibility will remain limited until DBS can be used which requires
validation of the DBS methodology by more laboratories (66). The assay does
yield accurate results on dried plasma spots (67) however DBS collection is
easier in the field and would therefore be the preferred sample.
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Viral detection assays are currently unavailable in the majority of low resource
settings and for the time being HIV antibody detection assays have to suffice.
Since it is less than ideal to diagnose HIV late in infancy, the efficacy of this
group of tests has to be maximised.
Manipulating HIV antibody detection assays to provide the earliest, most
accurate diagnosis possible was investigated by assessing two oral fluid HIV
antibody tests in this paper.
Oral fluid HIV tests are not FDA-approved for children under the age of 13 years.
The use of oral fluid instead of blood increases the accessibility and acceptability
of HIV testing since less skill is required to obtain the sample and sampling is
less painful. Oral fluid has a substantially lower total antibody concentration in
comparison to serum providing a naturally ‘dilute’ sample which would be
expected to reduce sensitivity of antibody detection, ideal for the setting of
reducing false positive results due to waning maternal HIV antibodies during
seroreversion. This paper demonstrates how effective oral fluid is in reducing the
need for repeat testing at 12 months of age and outlines issues that require
further research. The sample size of 321 children was comprised predominantly
of study patients in addition to infants presenting to the CWCH PMTCT clinic for
a diagnosis of HIV infection status. Informed consent was obtained for all infants.
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The outcome of the cost analysis substudy is detailed here. The main study was
concerned with assessing various age-appropriate HIV tests to provide evidence
for the accuracy of a new diagnostic algorithm. Examining the financial
implications of implementing this new algorithm is crucial in advocating for a
change in the HIV diagnosis policy. This paper measured the average cost of
ascertaining an infant’s HIV infection status for two diagnostic algorithms and
illustrates that using a cheaper HIV test late in infancy is costlier to society than
earlier testing with a more expensive HIV PCR test.
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5. CONCLUSIONS
The strength of the longitudinal study design was the ability to assess the
accuracy of each HIV test in relation to the clinical HIV infection status of the
infant established over 12 months according to a ‘gold standard’ (3).
Furthermore, the HIV tests were performed at specific, tightly controlled ages
rather than the more commonly encountered range of ages. This has the
advantage of being able to inform practical diagnostic guidelines that take
cognisance of the healthcare visits infants are committed to such as
immunization schedules at 6 weeks and 14 weeks (3 months) of age.
The longitudinal design and low prevalence of breastfeeding were vital in
demonstrating that all HIV infection transmitted in-utero and intrapartum was
detected by HIV DNA PCR at 6 weeks of age contrary to earlier concerns (3, 50-
52).
The originality of the study is manifested by many firsts. The first
- assessment of the efficacy of the CWCH PMTCT program (Publication 1)
- demonstration of the accuracy of a single 6-week HIV DNA PCR result in
determining the HIV infection status of non-breastfed infants
(Publication 2)
- modification of the extraction method of the HIV DNA PCR assay for DBS
testing in high throughput laboratories ushering it into the realm of routine
diagnostics and the demonstration that it performed as well on DBS as on
liquid blood in 6-week old infants (Publication 3)
- assessment of the ultrasensitive p24 Ag assay for infant diagnosis in
subtype C virus (Publication 4)
- evaluation of two oral fluid HIV tests in children and the proposal of a
unique clinical setting in which oral fluid testing may be superior to blood
for excluding HIV infection (Publication 5)
- measurement of the cost of establishing an infant’s HIV infection status
(Publication 6)
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- illustration of how modifying serum HIV ELISA cutoff readings in 12-month
old infants can accelerate a definitive diagnosis (unpublished data).
In the ideal PMTCT setting assuming Nevirapine administration (68) and
exclusive formula feeding, the Health Systems Trust estimated that the HIV
transmission rate in South Africa could decrease from 35% to 13% at 6 months of
age (56). The CWCH PMTCT program demonstrated that the transmission rate
could be reduced below 9% at 3 months of age (Publication 1) which has been
confirmed by ongoing monitoring of the program. In 2003 after the FDA raised
questions regarding the HIVNET012 study and the Medicines Control Council
reviewed the use of Nevirapine for PMTCT, data from this study were used to
successfully support continued use of Nevirapine in national PMTCT programs
(Appendix 12).
The most outstanding achievement of this study was the adoption by the South
African National Department of Health in April 2004 of a new diagnostic algorithm
based on a single 6-week HIV DNA PCR test (Appendix 13) (69). Implementation
of the policy is evident by the more than 10 fold increase in number of HIV DNA
PCR tests being performed nationally and the National Health Laboratory
Services’ strategic plan to increase the number of laboratories capable of
performing HIV DNA PCR testing from three to 11 by the end of 2006 (personal
communication Dr T. Marshall).
The global commitment to providing antiretroviral treatment in low resource
settings cannot be achieved without a diagnosis of HIV infection. Hence this work
has attracted enormous interest from the international community culminating in
multiple invitations to present at Paediatric HIV Care Consultation meetings
hosted by CDC, WHO, UNICEF and ANECCA. It is widely quoted in the draft
WHO guidelines “Antiretroviral treatment of HIV infection in infants and children
in resource-limited settings, towards universal access: Recommendations for a
public health approach” due for release in 2006 (http://www.who.int/en/).
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Opportunities that have arisen from this work include an invitation to chair the
HIV Collaborative Forum’s (based in Washington D.C) recently launched
‘Pediatric HIV Diagnosis and Monitoring Working Group’ and chairing the ‘Early
identification Task Team’ established by the South African Concerned Child
Healthcare workers and the National Department of Health to improve the quality
of HIV care to children in this country.
Additional contributions include modification of the ultrasensitive p24 Ag assay
method for use on DBS to improve accessibility of the assay in low resource
settings (66), exploration of socio-economic reasons for the high loss to follow-up
rates at the CWCH PMTCT program (70), establishing decay patterns of the
K103N mutation after single-dose Nevirapine for PMTCT to inform treatment
decisions (71), insights into the psychosocial consequences of an early diagnosis
of infants (72) and disclosure issues in the context of vertical transmission (73).
Before DBS testing was adopted, further investigation was requested to
demonstrate that the HIV DNA PCR assay performed as well on DBS made from
heelpricks (capillary blood) as it did on DBS prepared from formal venesection
(venous blood). The latter was used in this study. Informed consent to perform
formal venesection as the ‘gold standard’ sample and a heelprick onto S&S 903
filter paper on the same child at a single visit was obtained. The sensitivity of the
heelprick sample was 98.3% due to a single false negative result and the
specificity was 98.6%. Although DBS are ideal for the clinical setting, in the
laboratory they are more laborious to process than liquid blood and investigation
of automated punches to overcome this is underway.
At commencement of this study in 2002, early infant diagnosis of HIV was a new
phenomenon in the public health care setting. According to the Child Care Act of
1983 informed consent had to be obtained from a parent or legal guardian. The
Act failed to recognize the reality of the situation in South Africa which was the
existence of substantial numbers of orphaned children who had neither parents
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nor legal guardians. In order to safeguard healthcare workers on this study and in
other situations dealing with HIV testing of children the Wits AIDS Law Project on
behalf of the Wits Paediatric HIV Working Group, obtained a High Court Order on
5 December 2003 to allow informed consent to be taken from the child’s primary
caregiver provided that an HIV test was in the best interest of the child (Appendix
14) (74). This set a precedent that has been incorporated into the new Children’s
Bill (75).
Following the global commitment to treating HIV infection in poorly resourced
settings, the need for diagnosing infants early has become evident and renewed
efforts in this field are manifested by investigation of DBS testing (67, 76-78), real
time PCR (77, 79), the ultrasensitive p24 Ag assay (80) and near patient testing
(81). Quantitative HIV RNA tests are required in low resource settings for
initiating and monitoring antiretroviral therapy. To reduce the panel of laboratory
tests necessary to manage the epidemic, these assays may emerge as the
logical choice for infant diagnosis but will require further validation (64, 79, 82,
83).
The results of this study have allowed additional funding to be secured for further
research and to support scale-up of infant diagnosis in South Africa.
Ongoing studies stemming from this work comprise
- assessment of other viral detection assays on DBS including use of real
time PCR and automated laboratory systems to increase capacity
- validation of the DBS Ultrasensitive p24 Ag method for 6-week old infants
- further evaluation of HIV antibody detection assays including 4th
generation and oral fluid HIV ELISA assays and rapid HIV tests.
A mobile ‘infant diagnostic team’ comprising a doctor and primary health care
nurse has been trained and will perform outreach work to initiate sustainable
infant diagnostic services in collaboration with the Gauteng Department of
Health’s HAST (HIV/AIDS and Sexually Transmitted diseases) Directorate.
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Funding to increase the capacity of the Johannesburg Hospital’s molecular
laboratory has been secured to launch DBS HIV DNA PCR testing and provide
laboratory training and support. Clinical and laboratory standard operating
procedures for infant diagnosis of HIV are being collated for widespread
dissemination nationally and internationally. Appendix 15 contains an example of
one of the clinical standard operating procedures developed from this study for
use in training to ensure good clinical practice.
Local and international clinical and laboratory collaborative networks as a result
of this study continue to expand and are essential to achieving rapid, global
scale-up of HIV diagnosis in infants. The world that once believed that HIV could
not be treated in low resource settings has witnessed heartening results with
antiretroviral therapy. Now it seems possible that HIV diagnosis in infancy may
also be attainable….
